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Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder closely linked with type II
diabetes (T2D). The progression of NAFLD is associated with the induction of lipogenesis
through hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1)
pathway. An increase in lipogenesis induces endoplasmic reticulum (ER) stress and
accelerates oxidative liver injury in the pathogenesis of NAFLD. Lobeglitazone, one of
thiazolidinediones (TZDs), is used as an antidiabetic drug to lower serum glucose level
through an increase in insulin sensitivity. It is known to improve pathological symptoms
in animals and humans with NAFLD. However, the underlying molecular mechanism of
the protective effects of lobeglitazone against NAFLD has not been elucidated. Here,
we show that under the physiological condition of acute lipogenesis, lobeglitazone
inhibits hepatic lipid synthesis, the subsequent ER stress, and ω-oxidation of fatty
acids by inhibiting the mTORC1 pathway. As a result, lobeglitazone protected mice
from lipogenesis-induced oxidative liver injury. Taken together, lobeglitazone might be
a suitable drug for the treatment of patients with diabetes and NAFLD.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD), encompassing a spectrum from simple steatosis to
non-alcoholic steatohepatitis (NASH), is associated with metabolic disorders such as obesity, type
II diabetes (T2D), and insulin resistance (1–3). Insulin resistance induces hepatic lipogenesis,
precipitating lipid accumulation and oxidative stress in the liver (4).
Hepatic lipogenesis is increased by expression of the basic helix-loop-helix-leucine zipper
(bHLH-Zip) transcription factors, such as sterol regulatory element-binding protein-1c (SREBP-
1c) and carbohydrate response element binding protein (ChREBP) (1, 5, 6). SREBP-1c is positively
regulated by hyperactivaiton of mechanistic target of rapamycin complex 1 (mTORC1) manifested
in NAFLD, which promotes lipid synthesis (7–9). Consequently, excess lipids induce stress in the
endoplasmic reticulum (ER) stress and theω-oxidation of fatty acids; in turn, this leads to oxidative
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stress in the liver. Thus, recent studies have revealed that
targeting of hepatic lipogenesis is a prospective therapeutic
strategy for the treatment of NAFLD (10).
Recently, several studies reported that thiazolidinediones
(TZDs), antidiabetic drugs for the treatment of T2D, prevent
the development of NAFLD in clinical data and in vivo
experiments (11–13). Lobeglitazone is a recently developed
TZD that increases insulin sensitivity through the promotion
of binding between insulin and its receptor in adipose tissue
(14, 15). Similar to other TZDs, lobeglitazone ameliorated
insulin resistance and hepatic steatosis (16, 17); however,
the detailed mechanism of its anti-steatotic effects remains
unclear. Thus, we investigated the effects of lobeglitazone and
molecular mechanisms of its action in the progression of
NAFLD.
MATERIALS AND METHODS
Antibodies and Reagents
Antibodies to S6, phosphorylated S6, phosphorylated P70S6K,
4EBP1, phosphorylated 4EBP1, Akt, phosphorylated Akt, mTOR,
and phosphorylated mTOR were purchased from Cell Signaling
Technologies. The antibody to P70S6K was purchased from
Cusabio. Lobeglitazone was generously supplied by Chong Kun
Dang Pharmaceutical Corporation (Seoul, Republic of Korea)
and dimethyl sulfoxide (DMSO) was purchased from Sigma
Aldrich.
Animals
Male C57BL/6J mice, 9–11 weeks of age, were purchased
from Japan SLC, Inc. (Hamamatsu, Japan). These animals were
randomly grouped into one of three types: animals administered
vehicle and fed a normal chow diet without fasting; animals
administered vehicle and fed a high-carbohydrate diet, fat-
free diet (HCD) after a 24 h fast; and animals administered
lobeglitazone or rapamycin and fed a HCD after a 24 h fast. All
mice were given free access to water and food in an environment
maintained at 23 ± 2◦C, 12/12 h light dark cycle, and between
50 and 70% humidity. Before vehicle, lobeglitazone (1 mg/kg), or
rapamycin (8 mg/kg) was administered by oral gavage, the mice
were fasted for 0 or 24 h and then given access to food. After 12 h
of feeding, the mice were sacrificed. All animal experiments were
approved by the Animal Care and Use Committee of the Yonsei
University College of Medicine.
Abbreviations: NAFLD, non-alcoholic fatty liver disease; T2D, type II diabetes;
mTORC1, mechanistic target of rapamycin complex 1; TZD, thiazolidinedione;
ER, endoplasmic reticulum; NASH, non-alcoholic steatohepatitis; SREBP-1c,
sterol regulatory element-binding protein-1c; ChREBP, carbohydrate response
element binding protein; HCD, high-carbohydrate diet, fat-free diet; ALT, alanine
aminotransferase; DG, diglyceride; TG, Triglyceride; ROS, reactive oxygen species;
GSTA1, glutathione S-transferase A1; NQO1, NAD(P)H quinone dehydrogenase
1; Cyp4α10, cytochrome P450 enzymes 4A10; Cyp4α14, cytochrome P450 enzymes
4A14; EMDM, ER degradation-enhancing α-mannosidase-like protein; Grp78, 78
kDa glucose-regulated protein; TRB3, tribbles pseudokinase 3; ATF4, activating
transcription factor 4; FAS, fatty acid synthase; ACC, acyl coenzyme A carboxylase;
SCD-1, stearoyl CoA desaturase 1.
Measurement of Serum ALT Levels
The blood obtained from heart of mice was incubated at
room temperature for 1 h, and then centrifuged at 3,000 rpm
for 10min. The resulting supernatants were collected in new
tube and measured by using a colorimetric assay kit (BioAssay
Systems) to qunatifiy serum alanine aminotransferase (ALT)
level.
Immunoblot Analysis
For immunoblot analysis, mice livers or primary hepatocytes
were homogenized in analysis buffer [50mM Tris-HCl (pH
7.5), 150mM NaCl, 1mM 4-(2-aminoethyl)-benzensulfonyl
floride, 1% NP-40, and protease inhibitors]. The cell lysates were
centrifuged and the resulting supernatants were collected
and measured by using the Bradford assay (Bio-Rad).
The cell lysates were separated by SDS-polyacrylamide gel
electrophoresis and transferred onto a polyvinylidene difluoride
membrane. The membranes were blocked, incubated with
primary antibodies overnight, and then incubated with
horseradish peroxidase (HRP)-conjugated secondary antibodies.
Protein staining was visualized by the application of enhanced
chemiluminescence reagents (Thermo Scientific), and the
abundance of phosphorylated forms of the protein was
quantitated by densitometric analysis of the immunoblots and
normalized to the total form of the protein, respectively.
Quantitative RT-PCR Analysis
Total RNA was isolated from liver tissue by using Trizol reagent.
The RNA was reverse transcribed into cDNA by using a cDNA
synthesis kit (TAKARA). The resulting cDNA was subjected to
real-time PCR analysis using SYBR R© Green and an ABI PRISM
7700 system (Applied Biosystems). Ribosomal RNA (18S) was
used as an internal control. The sequences of primers for mouse
cDNAs (forward and reverse, respectively) were as follows: FAS,
5′-GCTGCGGAAACTTCAGGAAAT-3′ and 5′-AGAGACGTG
TCACTCCTGGACTT-3′; SCD-1, 5′-CCGGAGACCCCTTAG
ATCGA-3′ and 5′-TAGCCTGTAAAAGATTTCTGCAAACC-
3′; ACC1, 5′-TGGACAGACTGATCGCAGAGAAAG-3′ and
5′-TAGCCTGTAAAAGATTTCTGCAAACC-3′; LCE, 5′-TGT
ACGCTGCCTTTATCTTTGG-3′ and 5′-GCGGCTTCCGAA
GTTCAA-3′; GPAT, 5′-CAACACCATCCCCGACATC-3′ and
5′-GTGACCTTCGATTATGCGATCA-3′; ATF4, 5′-ACACAG
CCCTTCCACCTC-3′ and 5′-CACGGGAACCACCTGGAG-3′;
EDEM, 5′-GGATCCCCTATCCCTCGGGT-3′ and 5′-GTTGCT
CCGCAAGTTCCAG-3′; TRB3, 5′-CTCTGAGGCTCCAGG
ACAAG-3′ and 5′-GGCTCAGGCTCATCTCTCAC-3′; Grp78,
5′-GAAAGGATGGTTAATGATGCTGAG-3′ and 5′-GTCTTC
AATGTCCGCATCCTG-3′; Cyp4α10, 5′-ACACTGCTCCGC
TTCGAACT-3′ and 5′-CAGCACAAGTCGGGCTAAGG-3′;
Cyp4α14, 5′-CCCCTCTAGATTTGCACCAGAT-3′ and 5′-TCC
CAATGCAGTTCCTTGATC-3′; CPT-1, 5′- CACCAACGGGCT
CATCTTCTA-3′ and 5′-CAAAATGACCTAGCCTTCTATCGA
A-3′; CHOP, 5′-CATACACCACCACACCTGAAAG-3′ and 5′-
CCGTTTCCTAGTTCTTCCTTGC-3′; SREBP-1c, 5′-GGAGCC
ATGGATTGCACATT-3′ and 5′-GGCCCGGGAAGTCACTGT-
3′; ChREBP, 5′-GTCCGATATCTCCGACACACTCTT-3′ and 5′-
CATTGCCAACATAAGCGTCTTCTG-3′; GSTA1, 5′-TGCCCA
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ATCATTTCAGTCAG-3′ and 5′-CCAGAGCCATTCTCAACT
A-3′; NQO1, 5′-TTCTCTGGCCGATTCAGAG-3′ and 5′-GGC
TGCTTGGAGCAAAATAG-3′; HO-1, 5′-GAGCAGAACCAG
CCTGAACTA-3′ and 5′-GGTACAAGGAAGCCATCACCA-3′;
PPARα, 5′-TCGGCGAACTATTCGGCTG-3′ and 5′-GCACTT
GTGAAAACGGCAGT-3′; PPARγ, 5′-CTCTCAGCTGTTCGC
CAA-3′ and 5′-CACGTGCTCTGTGACGATCT-3′; 18S, 5′-CGC
TCCCAAGATCCAACTAC-3′ and 5′-CTGAGAAACGGCTAC
CACATC-3′.
Histological Analysis
The liver tissues of mice were fixed in 10% neutral-buffered
formalin solution, embedded in paraffin, and sliced into 5-µm
sections. The liver sections were subjected to hematoxylin and
eosin (H&E) staining.
TUNEL Analysis
For the analysis of apoptosis in the liver tissue in mice, the
Click-iT Plus TUNEL assay kit (Life Technologies, C10617)
was used in accordance with the manufacturer’s instructions.
The fluorescence signals were detected by using a confocal
microscope (LSM 700, Carl Zeiss). The frequency of apoptotic
cells in the liver sections was quantified by the determination
of the percentage of TUNEL-positive cell in five random
microscopic fields per specimen.
Fatty Acid Profiling
To each 10mg aliquot of liver tissue, 1mL of 7% methanolic HCl
(Sigma-Aldrich) and 5 µg of non-adecanoic acid (C19:0, Sigma-
Aldrich) were added as an internal standard (18). Tissue samples
were placed on dry ice and then homogenized by ultrasonication
(30% amplitude; 4 s pulse/1 s pause) for 30min by using Vibra-
cell ultrasonic liquid processor (VCX130, Sonics & Materials,
Inc.) (19). Lipid hydrolysis and acidic transmethylation of fatty
acids in homogenates were performed at 100◦C for 2 h. After
the samples were cooled to room temperature, the methylated
fatty acids were extracted three times with 1mL of hexane.
The collected organic layer was evaporated under nitrogen and
reconstituted into 100 µL of hexane. The fatty acids were
then quantified by using GC-MS (GCMS-QP2010, Shimadzu)
equipped with a DB-5MS capillary column (30m × 0.25mm,
0.25µm, Agilent). The injection volume was 1 µL in 1:2 split
mode and helium was used as a carrier gas at a constant flow
rate of 1 mL/min. The injection temperature was 270◦C and
the column temperature program for separation was as follows:
an initial temperature of 70◦C for 1min, increased to 150◦C at
20◦C/min, increased to 180◦C at 6◦C/min, increase to 220◦C at
20◦C/min, held for 1min, increased to 240◦C at 4◦C/min, and
held for 17min, over a total period of 35min. Electron impact
(EI) at 70 eV and a source temperature of 200◦C was used for
compound ionization. The mass detection range between 40 and
500 m/z, with a scan rate of 2,500 s−1. For identification, the
retention index (RI) was measured by using an alkane mixture
(C7-C40, Sigma-Aldrich) and each peak in the spectrum was
compared with the NIST mass spectral library (NIST08). The
peak area of fatty acids was integrated by using the total ion
chromatogram and normalized to the internal standard.
Diglyceride (DG) and Triglyceride (TG)
Profiling
The internal standards, 1 µg DG (12:0/12:0) and 1 µg TG
(17:0/17:0/17:0), were spiked in 10mg of tissue sample (20). Each
aliquot was immersed in chloroform/methanol/water solution
(2:5:2, v/v/v, J.T. Baker) and extracted ultrasonically by using the
same parameters as for fatty acid profiling. Thereafter, liquid-
liquid extraction (LLE) was performed by the addition of 1mL
of chloroform and water. The organic layer was transferred
to a glass vial and the LLE was repeated three times. The
lipid extracts were filtered through a 0.2µm PTFE syringe
filter (Advantec) and the filtrates were evaporated to dryness
under nitrogen gas. Finally, the lipids were reconstituted in 200
µL of isopropanol. The prepared samples were injected into
Agilent 1290 HPLC equipped with BEH C18 column (2.1 ×
100mm, 1.7µm, Waters). The lipids were separated by using
a binary gradient elution with a flow rate of 0.15 mL/min
at 40◦C. Eluent A was acetonitrile/water (1:9, v/v, J.T. Baker)
and eluent B was isopropanol/acetonitrile (3:1, v/v, J.T. Baker);
both eluents were supplemented with 10mM ammonium acetate
and 0.1% formic acid (Sigma-Aldrich). The following gradient
conditions were used: 0min, 40% B; 5min, 70% B; 20min,
90% B; 25min, 100% B; 38min, 100% B; 40min, 40% B;
50min, 40% B. The separated compounds were detected by using
Agilent 6530 QTOF-MS. An electrospray source was operated
in positive ionization mode. The ion source parameters were
as follows: sheath gas temperature, 350◦C; sheath gas flow,
12 L/min; nebulizer, 40 psi; dry gas temperature, 325◦C; dry
gas flow, 11 L/min; capillary voltage, 4000V; nozzle voltage,
500V; fragmentor, 100V. Full scan data from 50–1,200 m/z
was collected in centroid mode. The lock-mass reference ions
(118.0863 and 922.0097 m/z) were delivered to the source
continuously during data acquisition for mass calibration.
Targeted MS/MS at collision energy of 20 eV was performed
to identify all the lipids. The peak area from the extracted
ion chromatogram (EIC) was measured by using MassHunter
software (Agilent). The area was normalized to the internal
standard for each species. The composition of the acyl chain in
each lipid was measured by the EIC of [M-fatty acyl chain+H]+
fragment ion.
Subcellular Fractionation
For each group, liver tissues were pooled for subcellular
fractionation. The liver tissues were homogenized in 1mL
buffer A containing 10mM HEPES (pH 7.9), 1.5mM MgCl2,
10mM KCl, 0.5mM DTT, and 0.05% NP40. The buffer was
supplemented with protease inhibitors. The liver homogenates
were centrifuged at 3,000 rpm for 10min at 4◦C; then
the resulting supernatant was used as cytosolic sample. The
pellet was re-suspended in 374 µL buffer B containing
5mM HEPES (pH 7.9), 1.5mM MgCl2, 0.2mM EDTA,
0.5mM DTT, 26% glycerol (v/v); and then 26 µl of 4.6M
NaCl. After homogenizing using syringe, it was on ice for
30min. the suspended pellet was centrifuged at 24,000 g for
20min at 4◦C. The resulting supernatant was used as nuclei
sample.
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Isolation of Rat Primary Hepatocytes and
Cell Culture
Male Sprague-Dawley rats were purchased from Japan SLC, Inc.
(Hamamatsu, Japan). Primary hepatocytes were isolated from
collagenase-perfused livers of male Slc:SD rats by a modification
of a previously described method (21). The isolated cells were
plated onto 6 cm dishes in 3ml of DMEM supplemented
with 5% FBS, 100 units/ml sodium penicillin, and 100µg/ml
streptomycin sulfate. After 4 h at 37◦C incubator in 5% CO2,
the attached cells were washed with PBS and then incubated
in M199 supplemented with 100 nM dexamethasone and 1 nM
insulin overnight as described in Chen et al. (22). And insulin
was treated to a final concentration of 100 nM in rat primary
hepatocytes.
Statistical Analysis
Data in the graphs were analyzed using the two-tailed Student’s
t-test for comparisons between two groups, or one-way ANOVA
with the Tukey honest significant difference post-hoc test for
multiple comparisons (SPSS 12.0K for Windows, SPSS, Chicago,
IL) to determine statistical significance. A value of P < 0.05 was
considered significant.
RESULTS
Lobeglitazone Ameliorates Liver Injury in
Response to Physiological Lipogenic
Stimulation
An increase of lipogenesis during the progression of NAFLD
is one of the most important sources of fatty acids that
contribute to the storage of TGs (23). Excess free fatty
acids increase the susceptibility of the liver to oxidative
stress. Thus, to examine whether lobeglitazone ameliorates
hepatic injury, mice were fasted and then refed with a
HCD, which are the physiological conditions that induce
lipogenesis (7, 24). Subsequently, mice were injected with
vehicle or lobeglitazone at 1 mg/kg by oral gavage before
refed with HCD. We found that lobeglitazone alleviated
refeeding-induced liver damage as measured by hematoxylin-
eosin (H&E) staining (Figure 1A). In support of this finding,
lobeglitazone decreased the increased ALT in physiological
lipogenic stimulation (Figure 1B). To test whether lobeglitazone
reduced liver injury-induced cell death, we stained a liver
section of mice by using a terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) assay kit (Figures 1C,D).
TUNEL-positive apoptotic cells were detected abundantly
after refeeding, but this was significantly attenuated by
lobeglitazone. The Nrf2 is master transcription factor for
elimination of ROS. To further verify whether lobeglitazone
attenuated the accumulation of reactive oxygen species (ROS)
under physiological lipogenesis conditions, we examined the
amount of nuclear Nrf2 by using nuclear fractionation
(Supplementary Figures 1A,B). We found that lobeglitazone
reduced translocation of Nrf2 into Nucleus, resulting in
downregulation of its target genes (Figure 1E). We observed that
lobeglitazone downregulated the activation of Nrf2 target genes
induced in the adaptive response to oxidative stress. Collectively,
these results indicated that lobeglitazone ameliorated oxidative
stress-mediated liver injury through the inhibition of ROS
generation.
Lobeglitazone Inhibits Fatty Acid
ω-Oxidation and ER Stress
Microsomal fatty acid ω-oxidation accelerates oxidative liver
injury in NAFLD because it results in a dramatic generation
of ROS (25). To explore whether lobeglitazone inhibited ω-
oxidation-mediated ROS production, we evaluated the mRNA
expression of cytochrome P450 enzymes 4A10 (Cyp4α10)
and 4A14 (Cyp4α14) by using qRT-PCR analysis (Figure 2A).
We found that lobeglitazone reduced the expression of ω-
oxidation-related genes activated by refeeding. In addition,
it has been reported that ROS was dramatically increased
by ER stress in NAFLD and that refeeding with HCD in
fasted mice induced hepatic ER stress (23, 24). Therefore,
to investigate whether lobeglitazone inhibited ER stress, we
evaluated the expression of ER stress-related genes, including ER
degradation-enhancing α-mannosidase-like protein (EMDM),
78 kDa glucose-regulated protein (Grp78), tribbles pseudokinase
3 (TRB3), and activating transcription factor 4 (ATF4) and
of CCAAT/enhancer-binding protein homologous protein
(CHOP), ER stress-induced apoptosis marker, and found
that lobeglitazone downregulated all the genes upregulated
by refeeding (Figure 2B and Supplementary Figure 2).
Taken together, these results suggested that lobeglitazone
prevented liver injury by reducing fatty acid ω-oxidation and ER
stress.
Lobeglitazone Inhibits Hepatic Lipid
Synthesis
In the progression of NAFLD, the increase of lipid synthesis in
the liver can promote ER stress and microsomal ω-oxidation.
To investigate whether lobeglitazone regulated lipogenesis in the
liver, we examined lipogenesis-related enzymes by using qRT-
PCR and profiled the corresponding product by using GC-MS
analysis (Figures 3A,B and Supplementary Figures 3A,B). We
found that lobeglitazone reduced the mRNA expression of
lipogenic genes induced by refeeding, as well as their products
synthesized in the liver. Although ChREBP was not altered
in fasting/refeeding, lobeglitazone reduced SREBP-1c and
ChREBP, which are two transcription factors that regulate
hepatic lipogenesis. We also examined the total amount of
and concentrations of DGs and TGs, most of which are
composed of two or three among these three fatty acids
(Figures 3C,D and Supplementary Figures 3C,D). We showed
that lobeglitazone significantly reduced the concentration
of DGs and TGs under physiological lipogenic conditions.
Increased malonyl-CoA inhibits β-oxidation through CPT-1
under acute lipogenic condition in hepatocyte; therefore, it
accumulates lipid in the liver (26). To determine whether
lobeglitazone affected fatty acid β-oxidation, we assessed
the levels of carnitine palmitoyltransferase 1 (CPT-1) as
measured by qRT-PCR analysis. We found that lobeglitazone
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FIGURE 1 | Lobeglitazone ameliorates acute lipogenic stimulus-mediated liver injury in mice. (A–E) Mice were maintained in a non-fasted state (NFa) (n = 8) or fasted
overnight and then refed a high-carbohydrate, fat-free diet (Fa/R) with vehicle (n = 9) or lobeglitazone (n = 9). (A) The liver sections from mice were stained by using
H&E. The extent of ballooning degeneration (arrow) is indicated on the bottom right set of images. CV, central vein. Scale bar = 200µm. (B) The serum alanine
aminotransferase (ALT) concentration was measured in each group of mice. (C) Images for TUNEL analysis of liver sections from each three groups of mice. Scale bar
= 100µm. (D) Quantitative graph of the TUNEL images of the liver sections. The data are the mean ± standard error for eight or nine mice of each group. *p < 0.05
and **p < 0.01. (E) Total RNA isolated from liver was subjected to qRT-PCR analysis of GSTA1 (top), NQO1 (middle), and p62 (bottom) mRNAs. The data are
presented relative to the corresponding value for non-fasted mice and are the mean ± standard error for eight or nine mice in each group. *p < 0.05, **p < 0.01, and
***p < 0.001.
increased the level of CPT-1, resulting in activation of
mitochondrial β-oxidation in physiological lipogenic conditions.
(Supplementary Figure 4). Collectively, these findings indicated
that lobeglitazone inhibited lipid accumulation through a
reduction in lipogenesis.
Lobeglitazone Inhibits the Activation of the
mTORC1 Signaling Pathway
Hepatic lipid synthesis is induced by the hyperactivation
of mTORC1 in NAFLD progression (7, 27, 28). Thus, to
investigate whether lobeglitazone inhibited the activation of
mTORC1, we analyzed the expression of mTORC1 signaling-
related proteins by using immunoblotting (Figures 4A,B).
It was identified that lobeglitazone downregulated the
refeeding-induced phosphorylation of S6, p70S6K, and 4EBP1.
Phosphorylated Akt can lead to activation of mTORC1 pathway
by inducing phosphorylation of mTOR at serine 2448 (8). To
further explore how lobeglitazone inhibited hyperactivation
of mTORC1, we examined the levels of phosphorylation
of Akt and mTOR as measured by immunoblot analysis
(Figures 4C,D). We observed that under physiological lipogenic
codintion, lobeglitazone reduced both phosphorylations
of Akt and of mTOR in the liver. Activation of mTORC1
negatively regulates activity of PPARα, which induces fatty
acid β-oxidation, and upregulates activity of PPARγ that
control expression of genes involved in lipid synthesis (29).
Consistent with these reports, we observed that lobeglitazone
upregulated expression of PPARα while it reduced expression
of PPARγ (Supplementary Figures 5A,B). Altogether, our
results suggested that lobeglitazone protected the liver from
lipogenesis-induced oxidative damage through the inhibition of
Akt-mediated mTORC1 activation.
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FIGURE 2 | Lobeglitazone inhibits ER stress and fatty acid ω-oxidation upon acute lipogenic stimulus in mice. (A,B) Mice were maintained in a non-fasted state (NFa)
(n = 8) or fasted overnight and then refed a high-carbohydrate, fat-free diet (Fa/R) with vehicle (n = 9) or lobeglitazone (n = 9). The isolated total RNA was subjected
to qR, Grp78, TRB3, and ATF4 mRNAs (B). The data are expressed relative to the corresponding value for non-fasted mice and are the mean ± standard error for
eight or nine mice in each group. *p < 0.05, **p < 0.01, and ***p < 0.001.
Inhibiting the Activation of the mTORC1
Protects Liver Against Oxidative Injury
From Physiological Lipogenic Stimulation
Rapamycin inhibits mTORC1 signaling under acute lipogenic
condition (8). To examine whether mTORC1 pathway
inactivated by rapamycin reduces lipogenesis, ω-oxidation,
and ER stress in this model, we subjected mice to fasting
followed by refeeding with a HCD and subsequently injected
with vehicle or rapamycin at 8 mg/kg by oral gavage before
refeeding with HCD. And then, we analyzed the expression of
mTORC1 signaling-related proteins by using immunoblotting
(Figures 5A–D). It was identified that rapamycin inhibited
activation of mTORC1 induced by refeeding with HCD. In
addition, we evaluated expression of lipogenesis-, fatty acid
oxidation-, and ER stress-related genes by using qRT-PCR
analysis (Figures 5E–H). We showed that rapamycin inhibited
expression of all genes except CPT-1 with inhibiting mTORC1
hyperactivation. Taken together, our data indicated that under
acute lipogenic condition, inhibition of mTORC1 ameliorated
not only increased lipogenesis, fatty acid ω-oxidation, and ER
stress but also blocked fatty acid β-oxiation.
To further verify whether inactivation of mTORC1 by
rapamycin improves acute lipogenesis-induced liver damage,
we measured refeeding-induced liver damage by using
hematoxylin-eosin (H&E) staining and serum ALT analysis
(Figures 6A,B). We observed that rapamycin ameliorates liver
injury in physiological lipogenic stimulation. Furthermore,
we found that rapamycin reduced refeeding-induced cell
death by using TUNEL assay kit (Figures 6C,D) In addition,
we investigated whether rapamycin downregulated Nrf2
activation increased under this oxidative stress condition,
we examined expression of Nrf2-dependent antioxidant
genes, including GSTA1, NQO1, and p62 (Figure 6E). We
found that rapamycin downregulated Nrf2 target genes.
Collectively, our results suggested that inhibiting mTORC1
activation protected the liver from lipogenesis-induced oxidative
damage.
Lobeglitazone Inhibits mTORC1 Signaling
in Rat Primary Hepatocytes
The mTORC1 signaling in rat primary hepatocytes treated
with insulin is induced by increase of phosphorylation of Akt
(8, 30). To investigate whether the effect of lobeglitazone on
mTORC1 in the liver is primary effect, we isolated rat primary
hepatocyte and treated insulin with or without lobeglitazone.
As results in mice, mTORC1 signaling was enhanced in insulin-
treated rat primary hepatocytes and alleviated in cells co-treated
with lobeglitazone (Figures 7A,B). Furthermore, Lobeglitazone
inhibited phosphorylation of Akt increased by insulin as in
liver tissue of mice (Figures 7C,D). Taken together, these results
suggested that lobeglitazone inhibits hepatic mTORC1 pathway
via reducing phosphorylation of Akt in both in vivo and in
vitro.
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FIGURE 3 | Lobeglitazone inhibits hepatic lipogenesis. (A–D) Mice were maintained in a non-fasted state (NFa) (n = 8) or fasted overnight and then refed a
high-carbohydrate, fat-free diet (Fa/R) with vehicle (n = 9) or lobeglitazone (n = 9). (A) The total RNA isolated from liver was subjected to qRT-PCR analysis of FAS,
SCD-1, and LCE mRNAs. The data are presented relative to the corresponding value for non-fasted mice. (B) The livers of eight or nine mice in each group were
homogenized. The lipids from the homogenates were subjected to hydrolysis and acidic transmethylation, and then detected by GC-MS. Fatty acid content of palmitic
acid, stearic acid, and oleic acid expressed per milligram of liver. (C,D) The livers of eight or nine mice in each group were homogenized. The lipids from the
homogenates were subjected to hydrolysis and acidic transmethylation, and then detected by LC-MS. Lipid content of DG and TG expressed per milligram of liver.
Data in (A,D) are the mean ± standard error for eight or nine mice in each group. *p < 0.05, **p < 0.01, and ***p < 0.001.
FIGURE 4 | Lobeglitazone inhibits mTORC1 signaling induced by acute lipogenic stimulus in liver. (A–D) Mice were maintained in a non-fasted state (NFa) (n = 8) or
fasted overnight and then refed a high-carbohydrate, fat-free diet (Fa/R) with vehicle (n = 9) or lobeglitazone (n = 9). (A,C) The livers from eight or nine mice of each
group were pooled and homogenized; subsequently, the homogenates were subjected to immunoblotting analysis with antibodies to the indicated proteins. (B,D) The
intensity of protein bands in (A,C, respectively) was determined by densitometry. The data in (B,D) are presented relative to the corresponding value for non-fasted
mice and are the mean ± standard error for eight or nine mice in each group. *p < 0.05, **p < 0.01, and ***p < 0.001.
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FIGURE 5 | Rapamycin inhibits acute lipogenesis-induced oxidative stress in liver. (A–H) Mice were maintained in a non-fasted state (NFa) (n = 4) or fasted overnight
and then refed a high-carbohydrate, fat-free diet (Fa/R) with vehicle (n = 4) or rapamycin (n = 4). (A) The livers from eight or nine mice of each group were pooled and
homogenized; subsequently, the homogenates were subjected to immunoblotting analysis with antibodies to the indicated proteins. The intensity of protein bands to
p-S6/S6 (B), p-4EBP1/4EBP1 (C), and p-p70S6K/p70S6K (D) in (A) was determined by densitometry. (E–H) The total RNA isolated from liver was subjected to
qRT-PCR analysis. FAS, SCD-1, and LCE mRNAs (E), CPT-1 mRNA (F), Cyp4α10, and Cyp4α14 mRNAs (G), and EDEM, Grp78, and TRB3 mRNAs (H). The data
are presented relative to the corresponding value for non-fasted mice. The data in (B–H) are presented relative to the corresponding value for non-fasted mice and are
the mean ± standard error for eight or nine mice in each group. *p < 0.05, **p < 0.01, and ***p < 0.001.
DISCUSSION
NAFLD is the most common chronic liver disease and is rapidly
increasing worldwide (31). NAFLD has known as a risk factor
for hepatic cirrhosis and hepatocellular carcinoma(32); however,
there are no pharmacological therapies approved for treatment of
NAFLD (10, 33).
In recent studies, TZDs, insulin sensitizers, have been
investigated as pharmacological therapy for treatment of NAFLD.
Several studies reported that pioglitazone and rosiglitazone
alleviated hepatic lipid accumulation and fibrosis in patients with
NAFLD. Furthermore, pioglitazone promoted hepatic fatty acid
oxidation in patients with NASH and reduced lipid synthesis in
human muscle (34–37). It was proposed that TZDs ameliorated
hepatic steatosis via the activation of the adiponectin-AMPK
axis (38); but, pioglitazone and rosiglitazone have diverse side
effects. Pioglitazone have the increased risks of bladder cancer
and rosiglitazone is associated with myocardial infarction and
cardiovascular mortality (39, 40); therefore, these are considered
significant due to clinical uses. Recently, Lobeglitazone was
developed as a more effective and safe TZD drug for treatment
of type II diabetes (41). Lobeglitazone has similar efficacy in lipid
metabolism to pioglitazone with even smaller dose in clinical
studies (42, 43). In addition, lobeglitazone showed markedly
reduction of adverse effects, such as cardiovascular disease
and bladder cancer (44, 45). TZDs including lobeglitazone
primarily act as PPARγ agonists in adipose tissue. As reported
by several studies, pioglitazone, and rosiglitazone, increased
uptake of fatty acids via activation of PPARγ in adipose
tissue and consequently reduced free fatty acids in plasma,
liver, or muscle. (46–48). Based on these reports, lobeglitazone,
similar to other TZDs, may alleviate NAFLD development by
increasing activity of PPARγ in adipose tissue. In addition,
a recent study reported that lobeglitazone attenuated hepatic
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FIGURE 6 | Inhibition of mTORC1 protects mice against acute lipogenic stimulus-mediated liver injury in mice. (A–E) Mice were maintained in a non-fasted state (NFa)
(n = 4) or fasted overnight and then refed a high-carbohydrate, fat-free diet (Fa/R) with vehicle (n = 4) or rapamycin (n = 4). (A) The liver sections from mice were
stained by using H&E. The extent of ballooning degeneration (arrow) is indicated on the bottom right set of images. CV, central vein. Scale bar = 200µm. (B) The
serum alanine aminotransferase (ALT) concentration was measured in each group of mice. (C) Images for TUNEL analysis of liver sections from each three groups of
mice. Scale bar = 100µm. (D) Quantitative graph of the TUNEL images of the liver sections. The data are the mean ± standard error for eight or nine mice of each
group. *p < 0.05 and **p < 0.01. (E) Total RNA isolated from liver was subjected to qRT-PCR analysis of GSTA1 (top), NQO1 (middle), and p62 (bottom) mRNAs. The
data are presented relative to the corresponding value for non-fasted mice and are the mean ± standard error for eight or nine mice in each group. *p < 0.05, **p <
0.01, and ***p < 0.001.
steatosis through the inhibition of PPARγ phosphorylation in
chronic obese mice (17); however, underlying mechanism of
the effects of lobeglitazone in NAFLD is still unclear. In our
study, we investigated under physiological lipogenic condition,
the effect of lobeglitazone and its molecular mechanism on the
progression of NAFLD, with a focus on lipogenesis in the liver
(Figure 8).
The mTORC1 signaling pathway is a central regulator of
lipid metabolism (49, 50). The hyperactivation of mTORC1
increased the gene expression of SREBP-1c in the liver
from patients with NAFLD (51). SREBP-1c is one of three
SREBP isoforms and transcriptionally activates lipogenic genes
(6). A recent study reported that the liver-specific knock-
out of mTORC1 markedly impaired SREBP1 function and
confers resistance to hepatic steatosis to mice (52). Thus,
mTORC1 signaling is required for hepatic lipogenesis via
the transcription of SREBP-1c (7, 8). Moreover, mTORC1
pathway upregulates peroxisome proliferator-activated receptor-
γ (PPARγ) leading to lipogenesis and adipogenesis while
negatively regulates peroxisome proliferator-activated receptor-
α (PPARα) that induces fatty acid β-oxidation (29). Recent
studies showed that activation of PPARγ induces hepatic
steatosis, and that lipid accumulation is exhibited in PPARα-
deficient mice (17, 53–57). Consequently, we found that
lobeglitazone reduced expression of PPARγ and induced
PPARα. Based on these findings, lobeglitazone is able to
inhibit progression of NAFLD via suppression of PPARγ-
induced adipogenic transformation of hepatocyte as well
as acute lipogenesis-induced oxidative stress by inhibiting
mTORC1 hyperactivation. The mTORC1 pathway can be
regulated by Akt (58, 59). The phosphorylated Akt induces
phosphorylation of mTOR at serine 2448 by inhibiting TSC2
or PRAS40, resulting in activation of mTORC1 pathway (8,
50, 60). Consistent with these reports, our results showed
that lobeglitazone lead to inhibit Akt-dependent mTORC1
activation under acute lipogenic stimulation. Since the upstream
events of the mTORC1 pathway are diverse, the reduction of
phosphorylation of Akt by lobeglitazone may be one of those
events. More detailed mechanisms should be studied in the
future.
An increase in hepatic lipogenesis by hyperactivation of
mTORC1 promotes lipid deposition and oxidative stress-induced
liver injury (1, 61). Free fatty acids increased by hepatic
lipogenesis were converted to TG and incapable of mitochondrial
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FIGURE 7 | Lobeglitazone inhibits insulin mediated stimulation of mTORC1 signaling in rat primary hepatocyte. (A–D) The isolated cells were incubated in M199
supplemented with 100 nM dexamethasone and 1 nM insulin overnight, and then insulin was treated to a final concentration of 100 nM with or without lobeglitazone.
(A,C) Primary hepatocytes isolated from rats were lysed and subjected to immunoblot anlaysis with antibodies to indicated proteins. (B,D) The intensity of protein
bands in (A,C, respectively) and was determined by densitometry. Data in (B,D) are presented relative to the corresponding value for only vehicle-treated cells and are
means ± Standard error for three independent experiments. *p < 0.05, **p < 0.01.
FIGURE 8 | Model for mechanism of protective action of lobeglitazone against
the liver injury. See text for details.
β oxidation through the inhibition of CPT-1, resulting in fatty
acid overload in hepatocytes (5, 62). Consequently, saturated and
unsaturated fatty acids may go through microsomal ω-oxidation
by CYP4A enzymes. Although ω-oxidation in microsome is a
minor pathway of fatty acid metabolism, it significantly can be
increased in liver overloaded with fatty acids (25). Fatty acid
ω-oxidation generates ROS, which is the major microsomal
sources of oxidative stress in NAFLD (63). Here, we found that
lobeglitazone inhibited the expression of ω-oxidation-related
genes.
Furthermore, fatty acid overload in the liver modifies the
lipid composition of ER membrane, which triggers ER stress
(1, 23, 64). The increased ER stress in NAFLD progression not
only acts as another inducer of oxidative stress, but also plays
a causative role in the process of lipogenesis (27, 65). In our
findings, lobeglitazone reduced ER stress via inhibiting lipid
synthesis. Nrf2 is known as the master transcription factor for
the antioxidant response, and can attenuate oxidative stress-
induced liver injury by eliminating accumulated ROS (66, 67).
Our results showed that lobeglitazone prevented the generation
of ROS through inhibition ofω-oxidation and ER stress, resulting
in reduction of Nrf2 target genes under acute lipogenic condition.
Consequently, lobeglitazone protects the liver from oxidative
stress-mediated injury. Collectively, these results support that
lobeglitazone exerts hepatoprotective effects by inhibiting hepatic
lipogenesis as well as increasing insulin sensitivity; thus, we
have suggested that lobeglitazone may be clinically used as a
therapeutic drug for NAFLD.
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